Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

RELiZORB®

K-Number: K232784 · 2023-12-21

ApplicantAlcresta Therapeutics, Inc.
Decision Date2023-12-21
Product CodePLQ
Advisory CommitteeGU
DecisionSubstantially Equivalent

Device Summary

RELiZORB® is a medical device manufactured by Alcresta Therapeutics, Inc.. It received FDA 510(k) clearance on 2023-12-21 under approval number K232784. The device is classified under product code PLQ. It was reviewed by the GU advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the RELiZORB®?

RELiZORB® is a medical device that received FDA 510(k) clearance on 2023-12-21. It is manufactured by Alcresta Therapeutics, Inc.. The 510(k) number is K232784.

When was RELiZORB® approved by the FDA?

RELiZORB® received FDA 510(k) clearance on 2023-12-21, under approval number K232784.

What company makes RELiZORB®?

RELiZORB® is manufactured by Alcresta Therapeutics, Inc..

What is the FDA product code for RELiZORB®?

The FDA product code for RELiZORB® is PLQ.

Other Devices by Alcresta Therapeutics, Inc.

K161247Relizorb K163057Relizorb K191379RELiZORB K231156Enzyme Packed Cartridge - RELiZORB K250499RELiZORB (100300/100301) K243284RELiZORB (100300/ 100301)

View all 7 devices →

Related Devices (Code: PLQ)

K161247RelizorbAlcresta Therapeutics, Inc. K163057RelizorbAlcresta Therapeutics, Inc. K191379RELiZORBAlcresta Therapeutics, Inc. K231156Enzyme Packed Cartridge - RELiZORBAlcresta Therapeutics, Inc. K250499RELiZORB (100300/100301)Alcresta Therapeutics, Inc. K243284RELiZORB (100300/ 100301)Alcresta Therapeutics, Inc.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑